Blue Jet Health

how big is Blue Jet Health?

As of Jun 06, Blue Jet Healthcare Ltd has a market capitalization of 15,762.00 Cr, with recent net sales of 1029.99 Cr and a net profit of 305.21 Cr.

Market Cap: As of Jun 06, Blue Jet Healthcare Ltd has a market capitalization of 15,762.00 Cr, categorizing it as a Mid Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Blue Jet Healthcare Ltd reported Net Sales of 1029.99 Cr and a Net Profit of 305.21 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The Balance Sheet data is Consolidated and pertains to the latest annual period of Mar'21. The Shareholder's Funds are valued at 339.82 Cr, while the Total Assets amount to 536.27 Cr.

What does Blue Jet Health do?

Blue Jet Healthcare Ltd is a mid-cap company in the Pharmaceuticals & Biotechnology sector, reporting net sales of 340 Cr and a net profit of 110 Cr for March 2025. It was incorporated in 1968, rebranded in 2020, and has a market cap of Rs 15,577 Cr.

Overview:<BR>Blue Jet Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Mid Cap company.<BR><BR>History:<BR>The company was originally incorporated as Jet Chemicals Private Limited in 1968. It changed its name to Blue Jet Healthcare Private Limited in December 2020 and became a Limited Company with its current name on May 18, 2022. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>- Net Sales: 340 Cr (Quarterly Results - Mar 2025)<BR>- Net Profit: 110 Cr (Quarterly Results - Mar 2025)<BR>- Market Cap: Rs 15,577 Cr (Mid Cap)<BR><BR>Key Metrics:<BR>- P/E: 52.00<BR>- Industry P/E: 53<BR>- Dividend Yield: 0.11%<BR>- Debt-Equity: -0.25<BR>- Return on Equity: 26.94%<BR>- Price to Book: 14.12<BR><BR>Contact Details:<BR>Registrar Address: Not available.

Who are in the management team of Blue Jet Health?

As of March 2023, the management team of Blue Jet Health includes Akshay Bansarilal Arora (Executive Chairman), Shiven Akshay Arora (Managing Director), Naresh Suiyakant Shah (Executive Director), and several Independent Directors: Girish Paman Vanvari, Preeti Mehta, and Divya Momaya, along with Sweta Poddar (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operations.

As of March 2023, the management team of Blue Jet Health includes the following individuals:<BR><BR>1. Akshay Bansarilal Arora - Executive Chairman<BR>2. Shiven Akshay Arora - Managing Director<BR>3. Naresh Suiyakant Shah - Executive Director<BR>4. Girish Paman Vanvari - Independent Director<BR>5. Preeti Mehta - Independent Director<BR>6. Divya Momaya - Independent Director<BR>7. Sweta Poddar - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational management of the company.

Has Blue Jet Health declared dividend?

Yes, Blue Jet Healthcare Ltd has declared a 50% dividend, amounting to 1 per share, with an ex-date of September 17, 2024. While the company has shown strong price returns of 80.89% over the last six months and 141.24% over the past year, dividend returns remain minimal.

Blue Jet Healthcare Ltd has declared a 50% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 50%<BR>- Amount per share: 1 per share<BR>- Ex-date: 17 Sep 24<BR><BR>Dividend Yield: 0.11%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 80.89%, with no dividend return, resulting in a total return of 80.89%.<BR><BR>Over the past year, the price return reached 141.24%, with a dividend return of 0.27%, leading to a total return of 141.51%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, there were no price or dividend returns, leading to a total return of 0.0%.<BR><BR>For the 4-year period, the price return and dividend return were both 0%, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, there was no price return or dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Blue Jet Healthcare Ltd has declared a dividend, the company has shown significant price returns over the past year and six months, but the dividend returns have been minimal in comparison.

Who are the peers of the Blue Jet Health?

Blue Jet Health's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Neuland Labs, Sanofi India, Alivus Life, and Granules India. Blue Jet Health has the highest 1-year return at 139.99%, significantly outperforming its peers.

Peers: The peers of Blue Jet Health are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Neuland Labs., Sanofi India, Alivus Life, and Granules India.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Neuland Labs., and Sanofi India, while Good management risk is found at Divi's Lab., Torrent Pharma, Blue Jet Health, Alivus Life, and Granules India. Below Average growth is noted for Divi's Lab., Torrent Pharma, Blue Jet Health, Sanofi India, Alivus Life, and Granules India, while Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, with Average growth at Neuland Labs. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, Dr Reddy's Labs, Blue Jet Health, Neuland Labs., Sanofi India, Alivus Life, and Granules India, while Good capital structure is observed at Torrent Pharma.<BR><BR>Return Snapshot: Blue Jet Health has the highest 1-year return at 139.99%, while Sanofi India has the lowest at -28.96%. Blue Jet Health's return significantly outperforms all peers. Additionally, the six-month return is negative for Neuland Labs., Sanofi India, and Alivus Life.

When is the next results date for Blue Jet Health?

The next results date for Blue Jet Health is 22 July 2025.

The next results date for Blue Jet Health is scheduled for 22 July 2025.

Who are the top shareholders of the Blue Jet Health?

The top shareholder of Blue Jet Health is Akshay Bansarilal Arora, holding 68.99%. Other shareholders include mutual funds at 0.5%, foreign institutional investors at 1.97%, and individual investors with a collective holding of 8.03%.

The top shareholders of Blue Jet Health include the promoters, with Akshay Bansarilal Arora being the individual with the highest holding at 68.99%. Additionally, the company has mutual funds holding 0.5% through 8 schemes and foreign institutional investors (FIIs) holding 1.97% across 53 FIIs. Individual investors collectively hold 8.03% of the shares. There are no significant public shareholders listed.

Is Blue Jet Health technically bullish or bearish?

As of November 3, 2025, Blue Jet Health's technical trend has shifted to a moderately bearish stance, indicated by a bearish MACD, moving averages, and Bollinger Bands, suggesting a negative outlook in the near term.

As of 3 November 2025, the technical trend has changed from mildly bearish to bearish. The current technical stance for Blue Jet Health is bearish with a moderate strength. Key indicators driving this stance include a bearish MACD on the weekly timeframe, bearish moving averages on the daily timeframe, and a mildly bearish reading on the weekly Bollinger Bands. Additionally, the Dow Theory indicates a mildly bearish trend on the weekly chart. Overall, the combination of these indicators suggests a negative outlook for the stock in the near term.

How has been the historical performance of Blue Jet Health?

Blue Jet Health experienced a decline in net sales and profit from March 2020 to March 2021, with net sales dropping to 498.93 Cr from 538.20 Cr and profit after tax decreasing to 135.79 Cr from 144.96 Cr. Despite this, the company saw an increase in total assets and a significant rise in cash inflow.

Answer:<BR>The historical performance of Blue Jet Health shows a decline in net sales and profit from March 2020 to March 2021.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2021, Blue Jet Health reported net sales of 498.93 Cr, down from 538.20 Cr in the previous year. Total operating income also decreased to 498.93 Cr from 538.20 Cr. The raw material cost rose to 214.27 Cr from 186.60 Cr, while the total expenditure, excluding depreciation, fell to 292.88 Cr from 324.47 Cr. Operating profit (PBDIT) decreased slightly to 214.93 Cr from 219.54 Cr, and profit before tax declined to 184.66 Cr from 194.13 Cr. Consequently, profit after tax also dropped to 135.79 Cr from 144.96 Cr. The earnings per share (EPS) saw a significant reduction, falling to 27.4 from 483.2. On the balance sheet, total liabilities increased to 536.27 Cr from 373.85 Cr, while total assets rose to 536.27 Cr from 373.85 Cr. The company experienced a net cash inflow of 51.00 Cr in March 2021, compared to 5.00 Cr in March 2020, with closing cash and cash equivalents increasing to 61.00 Cr from 10.00 Cr.

Is Blue Jet Health overvalued or undervalued?

As of November 25, 2025, Blue Jet Health is considered very expensive and overvalued, with a PE ratio of 27.80 and lagging behind the Sensex with a year-to-date return of -0.49%.

As of 25 November 2025, Blue Jet Health's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived valuation. The company is currently considered overvalued. Key ratios include a PE ratio of 27.80, an EV to EBIT of 22.46, and a Price to Book Value of 7.80, all of which suggest a high valuation relative to earnings and asset value.<BR><BR>In comparison to its peers, Blue Jet Health's valuation metrics are notably elevated; for instance, Poly Medicure has a PE ratio of 53.35 and an EV to EBITDA of 40.61, while Vimta Labs shows a PE of 44.86 and an EV to EBITDA of 24.04, both categorized as very expensive. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -0.49% compared to the Sensex's 8.25%, reinforcing the notion of overvaluation.

Are Blue Jet Healthcare Ltd latest results good or bad?

Blue Jet Healthcare Ltd's latest Q3 FY26 results are unfavorable, showing a 59.42% year-on-year decline in net profit and a 39.57% drop in net sales. The company's performance raises concerns about its financial health, with a negative outlook and significant stock underperformance.

Blue Jet Healthcare Ltd's latest results for Q3 FY26 indicate a significant decline in performance, which can be characterized as unfavorable. The company reported a net profit of ₹40.17 crore, reflecting a substantial decrease of 59.42% year-on-year and a 22.96% decline compared to the previous quarter. <BR><BR>Net sales also fell sharply, down 39.57% year-on-year to ₹192.41 crore, although there was a sequential improvement of 16.27% from the previous quarter. The operating margin has dropped to 24.36%, marking the lowest level in eight quarters, and the PAT margin decreased to 20.88%, down 1,021 basis points year-on-year.<BR><BR>These results represent a stark contrast to the company's strong performance in the first half of FY26, raising concerns about its operational challenges and overall financial health. The stock has underperformed significantly, down nearly 48% over the past year, which has led to a negative financial trend rating. Investors are left questioning whether this downturn is a temporary setback or indicative of deeper issues within the company. <BR><BR>Overall, the latest results suggest that Blue Jet Healthcare is currently facing serious challenges, making the outlook appear negative.

Should I buy, sell or hold Blue Jet Healthcare Ltd?

Why is Blue Jet Healthcare Ltd falling/rising?

As of 05-May, Blue Jet Healthcare Ltd's stock price is rising to Rs 490.70, with a 3.01% increase today and a 37.51% rise over the past month, indicating strong short-term performance despite some recent challenges. The stock's positive momentum is supported by increased investor interest and favorable sector trends.

As of 05-May, Blue Jet Healthcare Ltd's stock price is rising, currently at Rs 490.70, reflecting a change of Rs 14.35 or 3.01%. The stock has shown a significant increase of 10.73% over the past week and a remarkable 37.51% over the past month, indicating strong short-term performance. Additionally, the stock has been gaining for the last two days, with a total return of 10.39% during this period.<BR><BR>Despite today's performance underperforming its sector by 1.7%, the overall upward trend can be attributed to several factors. The stock's price has reached an intraday high of Rs 493.5, and it is currently trading above its 5-day, 20-day, 50-day, and 100-day moving averages, which suggests positive momentum. Furthermore, there has been a notable increase in investor participation, with delivery volume rising by 28.84% compared to the 5-day average, indicating growing interest in the stock.<BR><BR>On a broader scale, the medical equipment sector, in which Blue Jet operates, has gained by 4.49%, contributing to the stock's positive movement. The company's strong management efficiency, reflected in a high return on equity (ROE) of 23.50%, and its net-debt-free status further bolster investor confidence.<BR><BR>However, it is important to note that the company has faced challenges, including negative results reported for December 25, with net sales falling by 34.7% compared to the previous four-quarter average. Despite these negative factors, the recent performance and sector trends appear to be driving the stock's current rise.

Which are the latest news on Blue Jet Health?